Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates

Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of$ 0.47. This compares to loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -2.13%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of$ 0.49 per share when it actually produced a loss of $0.40, delivering a surprise of 18.37%. Over the last four quar ...